Drug effects and poisoning must be considered when trying to identify the cause of bizarre or unexplained illness. Accurate, timely and confident identification of an unknown agent poses a challenge to the toxicology laboratory and may carry medico-legal implications. We describe a case of fatal poisoning, shown after death to be due to isoniazid, and discuss the approach to the problem of identifying this unexpected toxic agent.
A 53-year-old man was admitted as an emergency in status epilepticus. He had a history of chronic alcoholism and post traumatic epilepsy. Two years prior to admission he sustained a head injury whilst inebriated. A right subdural haematoma developed, necessitating evacuation and a partial right temporal lobectomy. Subsequently, he developed grand mal convulsions which were treated with phenytoin. He complied poorly with treatment and continued to abuse alcohol, resulting in frequent admissions with uncontrolled epilepsy. No other history was available. Administration of a total of 10 mg rectal diazepam and 20 mg intravenous diazepam failed to abolish seizure activity but fitting stopped following two 5 mg doses of intra muscular paraldehyde. On examination post-ictally, he was hyperpyrexial (rectal temperature 42· 2°C), hypotensive (blood pressure 90/40 mmHg) and had a tachycardia (176 beats/min). He was unconscious with no spontaneous movement but responded to painful stimuli. Apart from generalized coarse crepitations in his lungs, there were no other significant abnormal findings.
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Chest X-ray showed shadowing at the left base. He was hyperkalaemic (potassium 6· 8 mmol/L) but blood gas analysis showed no significant acid base disturbance (pH 7'42, PC0 2 35 mmHg, P0 2 259 mmHg, bicarbonate 23 mmol/L; F~02 100070). Investigation of blood and cerebrospinal fluid was otherwise unremarkable. Alcohol, salicylate and paracetamol were not detected. Phenytoin in the admission blood sample was 7· 1 mg/L (therapeutic range 7· 0-20 mg/L). Further toxicological analysis is described below. He was treated with intravenous antibiotics (cefuroxime and metronidazole) and his hyperkalaemia was corrected with intravenous dextrose and insulin. The hyperpyrexia responded to tepid sponging and fanning. He remained unconscious with a persistent tachycardia and 8 h after admission, he had a haematemesis and was noted to be bleeding from his mouth, gums and venepuncture sites. He was anuric and shocked with a partially compensated metabolic acidosis (arterial blood gases; pH 7· 35, PC0 2 29 mmHg, PO 92 mmHg, bicarbonate 16 mmol/L). 
Despite transfusion of fresh frozen plasma and inotropic support, his condition deteriorated further and he died 15 h after admission. Blood cultures were subsequently reported as sterile. Post-mortem examination revealed no focus of infection, malignancy or other obvious cause of DIC. There was evidence of early stress ulceration of the gastric mucosa. There was surgical absence of the right parieto-temporal region of the brain, right ventricular hypertrophy and minimal emphysema in both lungs. Other organs including the liver were essentially normal.
Admission and post-mortem blood samples were submitted to toxicological examination. No urine or gastric contents were available.
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TOXICOLOGICAL ANALYSIS
Screening test Post-mortem blood was examined first using the Toxi-Lab A thin layer chromatography system (Mercia Diagnostics Ltd, Guildford, UK). An unidentifiable compound was present reacting only at Stage 4 as a brown spot (RF value = 0'95).
The extraction was repeated and the solvent layer evaporated in a clean tube. The contents were redissolved in ethyl acetate for analysis by gas chromatography/mass spectrometry (GC/MS).
Gas chromatography Reagents
All solvents and reagents were of Analar Reagent grade where available.
Instrumentation
Gas chromatographic (GC) analyses were performed with a Varian Model 3400 GC attached to a Finnegan lTD 800 Ion Trap Detector. Injections (I JLL) were made manually in splitless mode into a 4 mm i.d. glass injection port liner, followed by an analysis on an SE54 Econo-Cap (Alltech Associates) 30 x 0·32 mm i.d. fused silica capillary column with a bonded stationary phase of 0·25 JLm film thickness. The operating conditions were as follows: helium carrier gas at a head pressure of 10 psi; column oven temperature programmed from 70 cC to 250 cC at 20°/min; initial time 1 min; purge on after 20 s; final time 5· 0 min; injector temperature 250 cC and the lTD transfer line temperature 21O c C. The lTD was used at the setting produced by the automatic tuning programme.
Identity
The ethyl acetate extract gave a single peak with a Kovats retention index (RI) of approximately 1660. Sixteen drugs with retention indices ± 10/0 of 1660 are listed in the appropriate RI tables.' All but four were eliminated because they produced a reaction pattern on Toxi-Lab different from the unknown.
The mass spectral pattern of the material at RI 1660, when searched using the Incos library, gave a coefficient of identity (fit) of 846 with isoniazid, absolute identity being defined as 1000.
A solution in methanol of isoniazid 10 mg/L (a gift from Lederle Laboratories, Gosport, UK) was injected onto the GC column. This gave a peak with a mean RI of 1662which was identified as isoniazid by the Incos library software with a fit of 854. The mass spectrum obtained on the Ann Clin Biochem 1995: 32 pure material gave a fit of 963. The GC peaks and related mass spectra are shown in Fig. 1 .
Finally, the extract of the post-mortem sample was run again on the Toxi-Lab A system without staining and the area of the chromatogram corresponding to R F = O' 95 eluted and reextracted into ethyl acetate as above. This extract also gave a single peak on GC with the same retention index as the direct extract of the patient's blood confirming that the unidentified spot on Toxi-Lab A was the same compound.
Quantitation
Isoniazid was quantitated in an admission blood sample. Insufficient post-mortem blood was available for analysis. Duplicate samples of the patients's blood and drug-free serum to which isoniazid had been added to give concentrations of 10, 50 and 100 mg/L were extracted according to the method of Lauterburg.? The final extractions were evaporated and redissolved in derivatizing agent (30 JLL bis [trimethyl silyl] trifluoracetamide [BSTFA] in Reactivials) and after 1 h at 80 cC for derivative formation, 1 JLL injected onto the column. Nicotine was used as internal standard in all standards and samples. The mean concentrations of isoniazid in duplicate samples of the patient's blood were 69· 3 and 70·4mg/L.
DISCUSSION
Intentional or accidental self-poisoning with the anti-tuberculous drug, isoniazid, can cause intractable seizures, coma, hypotension, hyperpyrexia, metabolic acidosis and disseminated intravascular coagulation. The major clinical features in this case can therefore all be explained by isoniazid poisoning. The concentration of isoniazid in the admission blood sample (70 mg/L) was grossly raised. Isoniazid levels can deteriorate in biological samples unless special precautions are taken, e.g. deproteinization of serum within 24 h of collection or extraction on the day of collection." In this case, analysis of the admission sample was carried out retrospectively thus the true concentration of isoniazid may have been even higher. Therapeutic doses produce plasma levels in the range 3-10 mg/L and fatalities have been reported with levels in the range 13-244 mg/L. 4 -6 Isoniazid can cause seizures in susceptible individuals even at therapeutic concentrations.
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The drug forms hydrazones with pyridoxal phosphate, depleting the coenzyme essential for Time (min'sl the synthesis of the inhibitory neurotransmitter, 'Y-aminobutyric acid (GABA) in the central nervous system. Administration of pyridoxine is therefore recommended as specific therapy to replenish GABA, although its efficacy has been difficult to determine because of the concurrent use of other anticonvulsants." Our patient had post-traumatic epilepsy and was a chronic alcoholic, both factors predisposing to isoniazid toxicity. Hyperpyrexia is a recognized complication of status epilepticus and the combination has previously been recorded in a 15-year-old girl who died following the ingestion of 5 g of isoniazid." Disseminated intravascular coagulation could have been consequent on the hyperpyrexia although this was readily controlled by simple cooling measures. However, isoniazid was thought to be the cause of DIC in a patient being treated for tuberculosis in whom no other aetiological factors could be identified and who recovered following withdrawal of the drug.? Thus, isoniazid may have directly led to DIC in our patient. It was not possible to establish with 
